Drug news
Takeda discontinues Rozerem for Insomnia in the EU
Takeda discontinues the development of Rozerem (ramelteon)the MT1 and MT2 receptor agonist for Insomnia in the EU following the withdrawal of its application for approval after a negative opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP).
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.